(BIAF) bioAffinity Technologies, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BIAF) bioAffinity Technologies, Inc. Complete Analysis Pack
bioAffinity Technologies: Business Model Canvas Snapshot
Explore how bioAffinity Technologies, Inc. creates value across its customer segments, key partners, revenue streams, and cost structure. This Business Model Canvas gives you a clear, strategic snapshot of the company’s operating model and growth levers. Want the full breakdown? Purchase the complete canvas for deeper insight and practical analysis.
Partnerships
Pulmonology and oncology referral sites
CyPath lung depends on pulmonology and oncology referral sites that spot suspicious lung nodules or elevated lung cancer risk and order the test. These referral ties are central to routine use because they drive both sample collection and repeat testing in real-world care, but bioAffinity Technologies has not disclosed a 2025/2026 referral-site count in public filings.
Clinical laboratory and specimen processing partners
bioAffinity Technologies, Inc. relies on clinical laboratory and specimen processing partners to handle sample prep, assay execution, and result reporting, so it can scale testing without building every step in-house. That setup helps protect turnaround time and quality control while keeping fixed lab costs lower than a full internal buildout.
Academic and medical research institutions
Academic and medical research institutions help bioAffinity Technologies, Inc. validate biomarkers, publish clinical evidence, and build trust in both diagnostics and therapeutics. In oncology, where adoption often depends on published data, these partnerships can speed proof points from lab to clinic and strengthen scientific credibility in 2025-2026.
Contract research organizations
Contract research organizations support bioAffinity Technologies, Inc. by running preclinical and clinical studies, handling study management, and generating data for precision-therapy programs. Using CROs lowers fixed overhead and can speed timelines, which matters when small biotechs need faster go/no-go decisions.
- Outsource study management
- Cut fixed costs
- Speed data generation
- Support precision therapeutics
Payers and reimbursement stakeholders
Payer coverage is a gating factor for bioAffinity Technologies, Inc. because reimbursement can turn clinical interest into paid test volume. With Medicare covering about 67 million people and U.S. private insurers handling most of the rest, payer talks, coding, and health system adoption decide whether a diagnostic scales or stalls.
- Coverage drives access and uptake
- Insurers shape paid test volume
- Coding supports reimbursement claims
- Health systems help validate utility
bioAffinity’s Partner Network Powers CyPath Lung Growth
bioAffinity Technologies, Inc. depends on pulmonology and oncology referral sites, lab partners, academic centers, CROs, and payers to move CyPath lung from order to reimbursement. These ties cut fixed costs, support clinical evidence, and help convert medical interest into paid test volume in 2025-2026.
| Partner | Why it matters |
|---|---|
| Pulmonology and oncology sites | Drive orders and repeat use |
| Payer coverage | About 67 million Medicare lives |
| CROs and labs | Scale studies and testing |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for bioAffinity Technologies, Inc. covering its diagnostics strategy, customers, channels, revenue, and key partnerships.
Customizable Excel Spreadsheet
Quickly spot bioAffinity Technologies’ key business model pain points with a clear, editable one-page snapshot.
Reference Sources
BioAffinity Technologies, Inc. Reference Sources provide a credible audit trail that supports faster, more confident investment and planning decisions.
Activities
CyPath lung assay development
In 2025, bioAffinity Technologies kept CyPath lung assay development at the center of its diagnostics work, refining sputum biomarkers, assay performance, and lab workflow to improve early lung-cancer detection in at-risk patients. The goal is a non-invasive test that can support faster triage before invasive follow-up.
Clinical validation studies
Clinical validation studies for bioAffinity Technologies, Inc. must prove CyPath Lung’s sensitivity, specificity, and real-world utility; published data have reported 92% sensitivity and 87% specificity, which helps build physician trust and supports reimbursement talks. That evidence also sharpens its case versus invasive options like bronchoscopy.
Laboratory testing and result reporting
Laboratory testing and result reporting are bioAffinity Technologies, Inc."s core operating task: samples must be received, analyzed, and reported with the same workflow every time. That consistency drives customer trust and repeat orders, because any delay or error can weaken use of the company"s diagnostic service.
Medical affairs and physician education
Medical affairs and physician education drive CyPath Lung adoption by showing clinicians when to order it and how to read the result. In a lung nodule market with millions of CT scans each year, clear guidance helps fit the test into care pathways, improve use, and support repeat orders.
- Explain use in indeterminate nodules
- Train on result interpretation
- Embed in care pathways
- Support market penetration and retention
Therapeutic target discovery
bioAffinity Technologies, Inc. uses therapeutic target discovery to look for actionable cancer biology at the cellular level, then screen compounds that can hit those targets. That can extend value beyond diagnostics by building a longer-term pipeline around targeted therapies.
- Identify actionable tumor biology
- Screen compounds against targets
- Expand value beyond diagnostics
bioAffinity Validates CyPath Lung With Strong 2025 Performance
In 2025, bioAffinity Technologies, Inc. focused on validating CyPath Lung, running lab testing and reporting, and training physicians on use in indeterminate lung nodules. It also advanced target discovery to expand beyond diagnostics. Published CyPath Lung data showed 92% sensitivity and 87% specificity.
| Key activity | 2025 data |
|---|---|
| CyPath Lung validation | 92% / 87% |
Preview Before You Purchase
Business Model Canvas
This preview shows the actual bioAffinity Technologies, Inc. Business Model Canvas you’ll receive after purchase. It’s not a sample or placeholder—what you see here is a direct preview of the final document. Once you complete your order, you’ll get the same fully formatted file, ready to edit, present, or share.
Resources
CyPath lung diagnostic platform
CyPath Lung is bioAffinity Technologies, Inc.’s flagship asset and the core of its commercial diagnostics push. It uses a non-invasive sputum sample to help assess early lung cancer risk, addressing a market where lung cancer still causes about 125,000 U.S. deaths a year and needs better early-screening tools.
Biomarker and assay intellectual property
BioAffinity Technologies, Inc.’s key resource is its biomarker and assay intellectual property, including patents, know-how, and proprietary methods that protect CyPath Lung’s test design and development work. That IP also strengthens future partnering and licensing talks by giving the Company defensible assets to monetize.
Clinical evidence and performance data
Clinical evidence and performance data are a core resource for bioAffinity Technologies, Inc. Its validation datasets help drive physician adoption, support payer discussions, and back scientific publication, while stronger performance data can separate CyPath Lung from competing tests.
Scientific and regulatory expertise
Scientific and regulatory expertise is a core resource for bioAffinity Technologies, Inc. Oncology diagnostics need validated assays, clinical proof, and compliance discipline to move from lab work into market use. The U.S. still expects 234,580 new lung cancer cases and 125,070 deaths in 2024, so getting accuracy and clearance right matters.
- Validates assay performance
- Supports clinical evidence
- Tracks FDA and quality rules
- Speeds commercialization
Management team and headquarters in San Antonio
bioAffinity Technologies, Inc. was founded in 2014 and is headquartered in San Antonio, Texas. Its management team and local operating base support product development and commercialization, giving the Company a clear execution hub in a state with a growing biotech footprint.
San Antonio also links bioAffinity Technologies, Inc. to the wider Texas life-science network, which helps with hiring, partnerships, and access to research talent.
- Founded: 2014
- Headquarters: San Antonio, Texas
- Role: development and commercialization
bioAffinity’s Core Assets Power CyPath Lung’s Growth
bioAffinity Technologies, Inc.'s key resources are its CyPath Lung IP, clinical validation data, and regulatory know-how. The Company was founded in 2014 and is based in San Antonio, Texas, giving it a small but focused operating hub for development and commercialization.
| Resource | Why it matters |
|---|---|
| IP | Protects CyPath Lung |
| Clinical data | Supports adoption |
| Team | Drives execution |
Value Propositions
Non-invasive lung cancer detection
CyPath Lung gives bioAffinity Technologies, Inc. a sputum-based option for non-invasive lung cancer detection, helping patients who may avoid bronchoscopy or biopsy. In the U.S., lung cancer is still expected to cause about 124,730 deaths and 226,650 new cases in 2025, so earlier visibility into possible disease can matter fast.
Early identification of high-risk patients
bioAffinity Technologies, Inc. targets patients with suspicious lung nodules or elevated lung cancer risk, where faster triage matters. In the U.S., localized lung cancer has a 5-year relative survival of about 65%, versus 28% overall, so earlier risk identification can help move the right patients to CT follow-up, biopsy, or surveillance sooner.
Support for reducing unnecessary invasive workups
bioAffinity Technologies, Inc. helps clinicians sort patients sooner and avoid low-value invasive workups. In lung nodule care, most nodules are benign, so a non-invasive test that adds to imaging and clinical judgment can reduce unnecessary biopsies, lower patient burden, and trim downstream costs.
Precision oncology discovery platform
bioAffinity Technologies, Inc.'s precision oncology discovery platform shifts the story from a single diagnostic test toward cell-level cancer treatment discovery. That broadens future optionality beyond diagnostics and, with no approved therapeutics yet, gives the Company Name a longer runway if its oncology pipeline converts.
Science-based clinical decision support
bioAffinity Technologies, Inc. anchors its value proposition in measurable biomarker science, so clinicians get a result they can trust and place in care. That matters in lung cancer, which caused about 1.8 million deaths worldwide in 2022, making evidence-based triage a real clinical need.
- Biomarker-led, not guesswork
- Supports clinical trust and adoption
- Fits high-need lung cancer decisions
CyPath Lung Speeds Risk Triage for Suspected Lung Cancer
bioAffinity Technologies, Inc. sells CyPath Lung as a non-invasive sputum test that helps sort higher-risk lung nodules sooner, before many patients face bronchoscopy or biopsy. With about 226,650 new U.S. lung cancer cases and 124,730 deaths expected in 2025, faster triage has clear clinical value.
| Data point | Value |
|---|---|
| U.S. new cases, 2025 | 226,650 |
| U.S. deaths, 2025 | 124,730 |
Customer Relationships
Physician-guided adoption
bioAffinity Technologies, Inc. depends on clinician judgment to order and read the test, so the relationship is built through physician education and workflow support, not direct consumer demand. In FY2025, that means trust from ordering doctors is the key driver of repeat use and broader adoption.
Account-based support for healthcare providers
bioAffinity Technologies, Inc.'s customer relationships are likely built around named accounts at practices, clinics, and health systems, so support stays close to ordering, specimen handling, and report delivery. This kind of account-based service keeps usage steady because providers need fast help to keep tests moving and results usable.
Medical affairs engagement
Diagnostics buyers want clinical proof, not ads: the global in vitro diagnostics market was about $111 billion in 2024, so medical affairs talks matter. By explaining study data, patient selection, and proper use, bioAffinity Technologies, Inc. can build trust with clinicians and labs in a technical market.
Technical and operational support
Technical and operational support matters because laboratory customers need dependable logistics and clear instructions to avoid sample errors and delays. For bioAffinity Technologies, Inc., smooth handling from order to result is what keeps CXCL3-based testing usable in day-to-day lab workflows.
- Clear steps lower sample rework.
- On-time logistics cut delays.
- Stable workflows lift satisfaction.
Support is part of the product experience, not a side service, and in lab testing even small process errors can disrupt turnaround time and customer trust.
Long-term recurring test relationships
bioAffinity Technologies, Inc. depends on repeat diagnostic orders, so revenue from customer relationships is built on consistency, not one-off sales. That makes retention as important as first-time adoption, because every clinic reordering in 2025 and 2026 supports recurring use, trust, and steadier cash flow.
- Repeat orders drive diagnostic revenue
- Trust and consistency keep clinics active
- Retention matters as much as adoption
Trust Drives Repeat Orders for bioAffinity’s Diagnostics
bioAffinity Technologies, Inc. builds customer ties through physician education, account support, and fast help on ordering and specimen handling, since clinicians drive use of the test. In 2025-2026, repeat orders and workflow reliability matter most because diagnostics revenue depends on trust, not one-time sales.
| Driver | Point |
|---|---|
| Trust | Clinician-led |
| Support | Order to result |
| Revenue | Repeat use |
Channels
Direct sales to clinicians and health systems
bioAffinity Technologies, Inc. can use a direct commercial team to reach ordering clinicians and health systems, which fits specialty diagnostics that need education before adoption. Direct contact helps turn awareness into test use faster, especially when providers need clear evidence on patient selection, workflow, and reimbursement.
Referral networks
Referral networks from pulmonology, oncology, and primary care are a practical volume engine for bioAffinity Technologies, Inc., because they send in patients already in the intended-use pool for lung cancer evaluation. Lung cancer still causes about 1.8 million deaths a year worldwide, so routing more of these high-risk referrals into testing can directly expand use.
Laboratory order workflow
Laboratory order workflow is a key channel for bioAffinity Technologies, Inc.: when test ordering and specimen logistics sit inside the clinical workflow, CyPath Lung is easier to use and adopt. Efficient design matters because small frictions in ordering, labeling, or transport can slow uptake and cut repeat use.
Scientific publications and conferences
Scientific publications and conferences give bioAffinity Technologies, Inc. peer-reviewed proof and live visibility, which is key for winning clinicians, researchers, and payers. In biotech, this channel helps explain clinical utility with data, not ads, so it can speed trust and adoption.
- Build credibility through peer review
- Reach clinicians and payers early
- Teach clinical utility with data
Company website and investor communications
bioAffinity Technologies, Inc. uses its website and investor pages to share product, science, and corporate updates, so customers and investors can track progress in one place. For a small biotech, these channels matter because they can reach a broad audience at low cost and support trust while the Company scales.
- Shares product and trial updates
- Explains science in plain language
- Supports investor trust and reach
How bioAffinity Drives CyPath Lung Adoption
bioAffinity Technologies, Inc. relies on direct sales, referral ties, lab workflow, and scientific proof to move CyPath Lung into use. These channels matter because lung cancer still causes about 1.8 million deaths a year worldwide, so faster routing of high-risk patients can raise test volume.
| Channel | Why it matters |
|---|---|
| Direct team | Educates clinicians |
| Referrals | Feeds intended-use patients |
| Publications | Builds clinical trust |
Customer Segments
Pulmonologists
Pulmonologists are a core customer segment for bioAffinity Technologies, Inc. because they evaluate patients with lung nodules, symptoms, or high risk, and their test ordering drives adoption. Lung cancer caused about 1.8 million deaths worldwide in 2022, so even small gains in earlier risk triage can affect a large patient pool.
Oncologists
Oncologists guide the next step after abnormal imaging, especially for lung nodules, where cancer remains the top cancer killer globally with about 2.48 million new cases and 1.82 million deaths in 2022. They need tools that improve early, accurate diagnosis and help them decide who needs biopsy, watchful waiting, or treatment.
Primary care physicians
Primary care physicians are the first stop for risk review, so they can spot eligible patients early and trigger referrals. With about 370,000 active primary care doctors and internists in the U.S., even small gains in test awareness can widen BioAffinity Technologies, Inc.'s funnel fast.
Hospitals and health systems
Hospitals and health systems are a fit for bioAffinity Technologies, Inc. because large providers buy once, then standardize across many sites. They focus on workflow, clinical value, and cost per test, so even small turnaround gains can matter in high-volume labs.
With about 6,000 U.S. hospitals and many multi-site systems, one adoption can turn into recurring orders and repeat use.
- Standardized pathways drive repeat volume
- Workflow speed matters most
- Cost impact shapes adoption
Patients at elevated lung cancer risk
Patients at elevated lung cancer risk are bioAffinity Technologies, Inc.’s core customer segment: adults 50-80 with a 20 pack-year smoking history, suspicious nodules, or other high-risk features. This is where earlier detection matters most, since lung cancer still causes about 1.8 million deaths a year worldwide and low-dose CT screening is aimed at catching disease sooner.
- High-risk adults
- Suspicious pulmonary nodules
- Earlier-detection need is strongest
bioAffinity Targets a Huge Lung Cancer Referral Network
bioAffinity Technologies, Inc. sells to pulmonologists, oncologists, primary care doctors, hospitals, and high-risk patients who need faster lung cancer risk triage. U.S. hospitals total about 6,000, and roughly 370,000 active primary care doctors and internists can feed referrals into screening and nodule workups.
| Segment | Why it matters |
|---|---|
| Pulmonologists | Order tests for nodules |
| Hospitals | Drive repeat volume |
Cost Structure
Research and development spend
Research and development spend is a core biotech cost for bioAffinity Technologies, Inc., funding biomarker discovery, assay improvement, and therapeutic research that drive future product performance and pipeline growth. In its latest annual filings, this line item remained a material operating expense, reflecting the ongoing investment needed to advance diagnostics and strengthen the Company Name’s technology base.
Clinical trial and validation costs
Clinical trial and validation costs are a major drag for bioAffinity Technologies, Inc., because evidence generation means study design, patient enrollment, sample analysis, and data management, often over 12 to 36 months. These programs can run into millions of dollars per study, but they are essential to prove commercial credibility and support adoption.
Laboratory operations and consumables
Running each diagnostic test uses reagents, materials, equipment time, and quality controls, so bioAffinity Technologies, Inc. carries a mostly variable lab cost base. That means test volume drives cost per unit: higher throughput can spread fixed equipment and quality-system costs, but weak volume can squeeze margins fast.
Sales, marketing, and physician education
bioAffinity Technologies, Inc. spends on sales, marketing, and physician education to build diagnosis adoption: account outreach, conference presence, travel, and training all push utilization. In 2025, these costs sat inside SG&A and rose with field activity, so each new account can lift near-term spend before revenue scales.
- Drives physician awareness
- Adds travel and conference cost
- Supports test adoption
General, administrative, and compliance costs
General, administrative, and compliance costs are fixed overhead for bioAffinity Technologies, Inc., covering finance, legal, HR, and healthcare regulatory work. In the latest reported filings, these costs also absorb SEC reporting, board governance, and audit support, so they scale with public-company duties more than with test sales.
- Fixed overhead for finance, legal, HR
- Supports SEC and healthcare compliance
- Includes governance and audit reporting
bioAffinity’s 2025 margins hinge on test volume growth
bioAffinity Technologies, Inc. has a cost base led by R&D, clinical validation, lab consumables, and SG&A, with fixed G&A/compliance overhead and variable per-test costs. In 2025, these spend lines stayed tied to assay development, evidence generation, and adoption work, so margin gain depends on higher test volume.
| Cost driver | 2025 takeaway |
|---|---|
| R&D | Core biotech spend |
| Clinical validation | High, study-linked cost |
| Per-test input | Variable with volume |
| SG&A | Adoption and outreach |
Revenue Streams
CyPath lung diagnostic test fees
CyPath lung diagnostic test fees are the core revenue stream for bioAffinity Technologies, Inc., with each completed test billed on a fee-for-service basis. That means revenue rises mostly with paid testing volume, so test adoption and reimbursement drive the business more than one-time product sales.
Insurance reimbursement and patient payments
Revenue depends on whether payers cover the test and how much patients pay out of pocket; when coverage is in place, more clinical orders turn into cash. For bioAffinity Technologies, Inc., reimbursement is the main scale lever, because each approved payer can lift conversion and support repeat use across larger patient volumes.
B2B laboratory service contracts
B2B laboratory service contracts can make bioAffinity Technologies, Inc. revenue steadier than claim-by-claim billing by locking in repeat test volume with health systems and partners. In its latest annual results, the Company reported about $1.4 million in revenue, so even modest contract wins can move the top line.
Development and collaboration agreements
bioAffinity Technologies, Inc. can earn development and collaboration revenue by using its therapeutics and diagnostics platform for partner-funded research, plus milestone-based payments when targets are met. This matters because it adds income beyond test sales and can smooth cash flow when product demand is uneven.
- Partner-funded R&D
- Milestone payments
- Less reliance on test sales
Future licensing or milestone income
If bioAffinity Technologies, Inc. expands targeted therapeutics or assay tech, licensing can add non-dilutive revenue through upfront fees, milestones, and royalties. In biotech, deals often pay in phases, so the same IP can earn cash at signing, development, and launch.
- Upfront fee at signing
- Milestones tied to progress
- Royalties on sales
- Upside from intellectual property
CyPath Lung Fees and Reimbursement Drive bioAffinity Revenue Growth
bioAffinity Technologies, Inc. Revenue Streams are led by CyPath lung test fees, with growth tied to paid test volume and payer coverage. In the latest annual results, bioAffinity Technologies, Inc. reported about $1.4 million in revenue, so reimbursement wins and partner contracts are the main cash drivers.
| Revenue stream | What drives cash | Latest cited data |
|---|---|---|
| CyPath lung test fees | Paid test volume | About $1.4 million revenue |
| Partner R&D and licensing | Milestones, royalties | Non-test upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.